Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19

• Status: Not yet recruiting
• Trial end date: 2022-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of high/low-dose cepharanthine for the Treatment of COVID-19 in asymptomatic and non-pneumonia mild adult participants with COVID-19 who do not need to be in the hospital, but in alternate care site.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Collaborator: YUNNAN BAIYAO GROUP CO.,LTD
• Treatments: Cepharanthine

Criteria

Inclusion Criteria:

• aged over 16 years old with all genders

• SARS-CoV-2 positive（laboratory-confirmed reverse transcription polymerase chain reaction (RT PCR) test)

• patient or immediate adult family member agrees to participate in this study and signs an informed consent form

• with mild covid-19 symptoms

• confirmed SARS-CoV-2 infection within 5 days prior to randomization

Exclusion Criteria:

• Confirmed SARS-CoV-2 infection within > 5 days prior to randomization

• CT shows pneumonia on admission

• diagnosed as severe or critical COVID-19 before intervention

• has a history of chronic underlying disease and acute exacerbation of that underlying disease at the time of admission

• Females who are pregnant or breastfeeding